PrimeRFP SCOUT · Federal Contract Recompete Brief

36C77026P0121Drospirenone — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). Competition previously drew 7 offers. Set-aside status: NONE. Recompete timing centers on the Sep 27, 2026 PoP end — agencies typically plan 12–18 months ahead.

National Cmop Office (36C770)

Awarding office

Amerisourcebergen Drug Corp

Recipient

Sep 27, 2026

PoP end

$321K

Obligated

$321K

Potential

325412

NAICS

6505

PSC

NONE

Set-aside

7 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

NONE

Contract number36C77026P0121

Also listed as36C770-26-P-0121

AgencyNational Cmop Office (36C770)

Awarding officeNational Cmop Office (36C770)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentAmerisourcebergen Drug Corp

CAGE1XUY5

UEIKABZK8W6PQT3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Place of performanceCONSHOHOCKEN PA

Pricing typeFirm Fixed Price

Extent competedCompeted Under SAP

Related solicitation36C77026Q0150

PoP startJul 17, 2026

PoP end (current)Sep 27, 2026

Obligated$321K

Current value$321K

Potential value$321K

DROSPIRENONE is a federal NONE award for National Cmop Office (36C770) held by Amerisourcebergen Drug Corp. Estimated value $321K ($321K obligated). Current period of performance ends Sep 27, 2026. Last award drew 7 bidders. Place of performance: CONSHOHOCKEN PA. Related solicitation 36C77026Q0150.

Recompete timing

Public

● Expiring in 37 days

Current PoP ends Sep 27, 2026 (37 days remaining). Agencies typically plan 12–18 months ahead — at 1.2 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies

Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C77026P0121?

36C77026P0121 (Drospirenone) is a National Cmop Office (36C770) award with a potential value of $321K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C770-26-P-0121?

36C770-26-P-0121 is the dashed form of PIID 36C77026P0121 (Drospirenone), held by Amerisourcebergen Drug Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C77026P0121?

National Cmop Office (36C770) awarded 36C77026P0121 to Amerisourcebergen Drug Corp (potential $321K).

Who is the incumbent on 36C77026P0121?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Sep 27, 2026.

When does Amerisourcebergen Drug Corp’s 36C77026P0121 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 27, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 11, 2026 · refreshed monthlyLatest procurement action Jul 15, 2026